D-0177-2021 Class II Terminated

Recalled by Imprimis NJOF, LLC — Ledgewood, NJ

FDA drug recall D-0177-2021 was initiated by Imprimis NJOF, LLC on Dec 17, 2020 and is designated Class II. Reason for recall: Lack of assurance of sterility: 13 vials were discovered to have faulty crimps. The recall status is terminated (terminated Aug 23, 2023). Affected quantity: 6520 vials.

Recall details

Product Type
Drugs
Report Date
Jan 6, 2021
Initiation Date
Dec 17, 2020
Termination Date
Aug 23, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6520 vials

Product description

Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979

Reason for recall

Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.

Distribution pattern

U.S.A. Nationwide

Code information

Lot#: 20JUN010, Exp 5/12/21

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0177-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0177-2021. Report a data issue: hello@regdatalab.com.